Bridge City Capital
LMAT icon

Bridge City Capital’s LeMaitre Vascular LMAT Stock Holding History

Bridge City Capital’s Portfolio LMAT Stock Details LMAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.7M Buy
116,980
+30,639
+35% +$2.71M 2.01% 7
2026
Q2 		$8.29M Buy
86,341
+15,951
+23% +$1.64M 1.89% 10
2026
Q1 		$7.68M Buy
70,390
+3,767
+6% +$359K 2.13% 8
2025
Q4 		$5.4M Sell
66,623
-7,235
-10% -$623K 1.59% 23
2025
Q3 		$6.46M Buy
73,858
+309
+0.4% +$27.6K 1.73% 15
2025
Q2 		$6.11M Sell
73,549
-824
-1% -$68.9K 1.71% 14
2025
Q1 		$6.24M Sell
74,373
-20,098
-21% -$1.87M 1.87% 10
2024
Q4 		$8.7M Buy
94,471
+6,430
+7% +$618K 2.32% 5
2024
Q3 		$8.18M Sell
88,041
-2,165
-2% -$188K 2.25% 3
2024
Q2 		$7.42M Buy
90,206
+17,002
+23% +$1.25M 2.49% 5
2024
Q1 		$4.86M Buy
73,204
+1,890
+3% +$117K 1.77% 7
2023
Q4 		$4.05M Buy
71,314
+12,453
+21% +$652K 1.57% 12
2023
Q3 		$3.21M Buy
58,861
+1,750
+3% +$104K 1.62% 11
2023
Q2 		$3.84M Sell
57,111
-15,960
-22% -$974K 1.82% 7
2023
Q1 		$3.76M Sell
73,071
-264
-0.4% -$12.8K 1.89% 7
2022
Q4 		$3.38M Sell
73,335
-513
-0.7% -$24K 1.73% 11
2022
Q3 		$3.74M Buy
73,848
+2,489
+3% +$124K 2.05% 7
2022
Q2 		$3.25M Sell
71,359
-128
-0.2% -$5.73K 1.72% 12
2022
Q1 		$3.32M Sell
71,487
-362
-0.5% -$16.2K 1.55% 15
2021
Q4 		$3.61M Buy
71,849
+640
+0.9% +$33.1K 1.49% 15
2021
Q3 		$3.78M Sell
71,209
-18,923
-21% -$1.07M 1.71% 11
2021
Q2 		$5.5M Sell
90,132
-3,003
-3% -$160K 1.88% 7
2021
Q1 		$4.54M Sell
93,135
-938
-1% -$44K 1.51% 11
2020
Q4 		$3.81M Sell
94,073
-977
-1% -$34.9K 1.45% 21
2020
Q3 		$3.09M Sell
95,050
-9,152
-9% -$275K 1.48% 21
2020
Q2 		$2.75M Buy
104,202
+3,272
+3% +$85.5K 1.26% 32
2020
Q1 		$2.52M Buy
100,930
+31,834
+46% +$983K 1.22% 36
2019
Q4 		$2.48M Buy
69,096
+13,237
+24% +$457K 1.02% 43
2019
Q3 		$1.91M Buy
55,859
+12,065
+28% +$385K 0.82% 61
2019
Q2 		$1.22M Buy
43,794
+193
+0.4% +$5.36K 0.67% 76
2019
Q1 		$1.35M Buy
+43,601
New +$1.16M 0.79% 66

Other funds holding LMAT

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Copeland Capital Management
Copeland Capital Management Conshohocken, Pennsylvania $4.34B AUM 17.52% 1-Year Est. Return
Conestoga Capital Advisors
Conestoga Capital Advisors Wayne, Pennsylvania $3.31B AUM 6.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Vest Financial
Vest Financial Mclean, Virginia $9.5B AUM 22.78% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
Linden Thomas Advisory Services
Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return

Bridge City Capital's LMAT Position: Q3 2026 in Review

Bridge City Capital increased its LeMaitre Vascular (LMAT) stake by 35% in Q3 2026, buying an estimated $2.71M and bringing the position to 116,980 shares worth $9.7M. The position accounts for 2.01% of the portfolio, ranked #7.

Bridge City Capital first reported a position in LMAT in Q1 2019 and has held it in 31 quarters since. 98 funds tracked by Wall St. Rank hold LMAT as of Q3 2026.

  • Bridge City Capital held 116,980 shares of LeMaitre Vascular worth $9.7M as of Q3 2026.
  • Bridge City Capital bought 30,639 LeMaitre Vascular shares in Q3 2026, an estimated $2.71M.
  • LeMaitre Vascular made up 2.01% of Bridge City Capital's portfolio in Q3 2026, its #7 holding.
  • Bridge City Capital first reported a position in LeMaitre Vascular in Q1 2019 and has held it in 31 quarters since.
  • 98 funds tracked by Wall St. Rank held LeMaitre Vascular as of Q3 2026.

Based on Bridge City Capital's 13F filing for Q3 2026, filed 29 Oct 2026.